Porphyrin complex and use thereof

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Kyoto University patent solves the following problem:

As is widely known, solar cells convert light energy into electricity which attract much attention as a future clean energy source. In particular, tina-sharpens solar cells using a dye allergies is easy to produce, and the cells will be given colorability, flexibility, etc. In doing so, they have other- other parts of the solar cells using silicon or an inorganic compound, and various intensive study and development. As a result, some of the solar cells using a dye allergies made a Ru complex (Ru-based dyes), for example, achieved efficiency in energy conversion (II ) more than 10%, and is expected to be put to practical use (nonpatent Document 1). However, a Ru-based dye used in an expensive, rare metal elements Ru, and thus there are problems of high production costs and limited resources. Therefore, there is a need for the development of an allergy dyes that are lower in cost and whose resources are very limited.

Our analysis of this patent is as follows:

Kyoto University’s patent US 8846905 B2 deals with Porphyrin complex and use thereof.
One thing the present invention is to provide a novel porphyrin complex with excellent natural light and a dye-sharpens solar cell use porphyrin complex as a dye allergies. The porphyrin complex of the present invention as a means for achieving the object is characterized by comprising a porphyrin derivative and a metal atom. The porphyrin derivative has a carboxyaryl group, optionally substituted aryl ring, included at least one of four Meso positions in a porphyrin ring optionally substituted -Position and also has a diarylamino group, optionally replaced by a ring or aryl, included at least either a Meso position beside it and a Meso position against it.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Solar module structures and assembly methods for pyramidal three-dimensional thin-film solar cells

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Solexel, Inc. patent solves the following problem:

Our analysis of this patent is as follows:

Solexel, Inc.’s patent US 8847060 B2 deals with Solar module structures and assembly methods for pyramidal three-dimensional thin-film solar cells.
Solar module structures and methods for gathering solar module structures. The solar module consists pyramidal structures three-dimensional thin-film solar cells arranged on the solar module structures. The pyramidal three-dimensional thin-film solar cell consists of a pyramidal three-dimensional thin-film solar cell substrate emitter junction regions and blast the base region. The three-dimensional thin-film solar cell further includes emitter metallization regions and the base metallization region. The three-dimensional thin-film solar cell substrate composed of a large pyramid-shaped cells in the unit. The solar module structure can be used in solar applications glass building façade applications, roof installed applications as well as for centralized solar power generation.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Multi-specific FAB fusion proteins and methods of use

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Fabion Pharmaceuticals, Inc. patent solves the following problem:

The present disclosure relates generally to multi-specific protein Fab fusion (MSFP). In particular, the MSFP the present disclosure includes an antibody Fab fragments with two N-termini fused to a fusion moiety by a cleavable or non-cleavable linker. The Fab fragments MSFP specifically bind to native cell surface target antigens as well as some sort of melt the same antigen. One or two fusion moieties bind specifically to the target antigens on the cell surface.

Our analysis of this patent is as follows:

Fabion Pharmaceuticals, Inc.’s patent US 8846042 B2 deals with Multi-specific FAB fusion proteins and methods of use.
The present disclosure relates generally to multi-specific protein Fab fusion (MSFP), which consists of an antibody Fab fragments with two N-termini fused to a fusion moiety (fusion moiety A or B). MSFP include Fab fragments exhibit significantly reduced cost ability to target Fab fragments Fab. Binding to Fab to target it restored when the MSFP clustered on a cell surface by binding together moieties their target. The reduced binding of Fab target, especially when presented on a cell surface in its native state, not fusion moiety rate provides advantages such as: reduced side effects and allow the desired medical effect on selectivity and specificity in a controlled manner.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

sVEGFR-2 and its role in lymphangiogenesis modulation

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The University Of Kentucky Research Foundation patent solves the following problem:

The homeostatic mechanism behind the loss of vasculature (blood and lymphatic vessels) in human and mouse cornea special interest given the highly vascularized nature of neighboring tissues, such as the ocular conjunctiva. This attitude avascular cornea made an important angiogenesis assay platform (Gimbrone et al, J. Exp Med, 136 (2): …. P 261-76, 1972) that allows scientists to study the pro – and / or anti-angiogenic effects of certain compounds in vivo. More than to serve as the basis for a model angiogenesis assay, the occurrence of corneal avascularity served important physiological functions. Corneal neovascularization, not be optimal vision and corneal compromise immunological privilege.

Our analysis of this patent is as follows:

University Of Kentucky Research Foundation’s patent US 8846386 B2 deals with sVEGFR-2 and its role in lymphangiogenesis modulation.
Disclosed here are nucleic acid molecules comprising a nucleotide sVEGF-2, the protein encoded in the file and antibodies that bind to the protein. Also disclosed are methods for inhibiting or enhancing the expression or activity sVEGFR-2 and methods for inhibiting graft rejection, especially cornea graph rejection. Also described are methods for inhibiting lymphangiogenesis and lymphatic endothelial cell proliferation by administering an effective amount of sVEGFR-2 and methods for treating lymphedema by inhibiting the activity of sVEGFR-2.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

AAV4 vector and uses thereof

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The The United States Of America, As Represented By The Secretary, Department Of Health And Human Services patent solves the following problem:

The present invention provides adeno-associated virus 4 (AAV4) and the vector obtained it. Thus, the present invention relates to AAV4 vector and means to deliver nucleic acid to cells in the subjects.

Our analysis of this patent is as follows:

The United States Of America, As Represented By The Secretary, Department Of Health And Human Services’s patent US 8846389 B2 deals with AAV4 vector and uses thereof.
The present invention provides an adeno-associated virus 4 (AAV4) virus and the vector particles are obtained. Furthermore, the present invention provides means for delivering a nucleic acid in a cell using AAV4 vector particles.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Infectious clones of torque teno virus

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Zoetis Llc patent solves the following problem:

Torque Teno Virus (TTV), also called transfusion-transmitted virus, often given to the family Circoviridae. It generally known as TTV first isolated from human patients fertilizers (see example, Nishizawa et al., Biochem. Biophys. Res. Comm. vol. 241, 1997, pp. 92-97). Thereafter, TTV or TTV-like viruses identified from other mammals, including pigs, and many types or isolates published (see for example, McKeown et al . Vet. Microbiol., Vol. 104, 2004, pp 113-117).

Our analysis of this patent is as follows:

Zoetis Llc’s patent US 8846388 B2 deals with Infectious clones of torque teno virus.
The present invention is directed to new nucleotide and amino acid sequences of torque teno virus (TTV), including its novel genotypes, all useful in preparing vaccines for treating and prevent disease in pigs and other animals. Vaccine is given according to the practice of the invention effective against multiple genotypes of swine TTV and isolating. Diagnostic and therapeutic polyclonal and monoclonal antibody also a part of the present invention, as the infectious clones useful in the propagation of the virus, and to prepare vaccines. Particularly important part of the vaccine formulation includes giving TTV ORF1 protein, or peptide fragments thereof, as antigen.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for treating synovial sarcoma

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Oncotherapy Science, Inc. patent solves the following problem:

Soft tissue sarcoma (STS) is a difficult disease to diagnose and treat. STSs often classified according to their histological appearance of mature, normal tissues (Weiss, HK and Goldblum, JR, Enzinger and Weiss's Soft Tissue tumors, 4th edition St. Louis :. Mosby, 2001). However, certain sarcomas such as synovial sarcoma (SS) without histological corresponding normal tissues, and therefore grouped together as miscellaneous soft tissue tumors (Weiss, HK and Sobin, L., Histological typing of soft tissue tumors: World Health Organization International Histological classification of Tumours, 2nd edition Berlin. Springer-Verlag, 1994). Synovial sarcoma usually affects the lower end of the teenagers and young adults 15-40 years of age (Weiss, 2001 supra). The clinicopathological calling originally given because SS occurs primarily in the vicinity of large joints and histologically similar to the development of synovium (Smith, L., Synoviomata Am J. Pathol, 3: 355, 1927). However, the subsequent immunohistochemical and ultrastructural studies (Ghadially, FN, Ultrastruct Pathol, 11: 147-51, 1987; Smith, ME et al, Histopathology, 26: 279-81, 1995) revealed significant differences between the tumor cells of the SS and the synovial cells. Moreover, SS can arise where synovial structure is unique or not, including in the lungs (Roberts, CA et al, Cancer genet Cytogenet, 88: 49-52, 1996). Heart (Iyengar, V. et al. arch Pathol Lab Med, 119: 1080-2, 1995), kidney (Argani, P. et al, Am J Surg Pathol 24: …. 1087-96, 2000), digestive tract (Billings, SD et al, Mod Pathol 13: 68-76, 2000), and bone marrow (Hiraga, H. et al, J. bone Joint Surg Am 81: 558-63 , 1999). Those data support the hypothesis that SS that originate from cells that are widely distributed in a variety of tissues.

Our analysis of this patent is as follows:

Oncotherapy Science, Inc.’s patent US 8846038 B2 deals with Method for treating synovial sarcoma.
By detecting synovial sarcoma using the differentially expressed gene expressed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Furthermore, a method for treating or preventing a disease associated with frizzled homologue 10 (FZD10) in a subject given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Low dose methods for treating disorders in which TNF activity is detrimental

File for Quick & Easy Patent Protection with PowerPatent.

The Abbvie Biotechnology Ltd. patent solves the following problem:

Tumor necrosis factor (TNF) is a cytokine produced by many cells, including monocytes and macrophages, that was originally identified based on its capacity to induce the necrosis of certain mouse tumors (see For example, Old, L. (1985) Science 230: 630-632). Human, something called cachectin, associated with cachexia, was shown to be the same molecule as TNF. TNF involved in mediating shock (see eg, Beutler, B. and Cerami, A. (1988) Annu Rev Biochem 57: 505-518; Beutler, B. and Cerami, A. (1989) Annu Rev. Immunol 7: 625-655). Moreover, TNF involved in the pathophysiology of a variety of other human diseases and disorders, including sepsis, infections, autoimmune diseases, transplant rejection and graft-vs-host disease (see for example, Moeller, A., et al. (1990) cytokine 2: 162-169; US Pat No. 5,231,024 to Moeller et al.; European Patent Publication No. 260 610 B1 Moeller, A., et al, Vasilli, P. (1992) Annu Rev Immunol. 10: 411-452; Tracey, KJ and Cerami, A. (1994) Annu Rev Med 45: 491-503) …

Our analysis of this patent is as follows:

Abbvie Biotechnology Ltd.’s patent US 8846046 B2 deals with Low dose methods for treating disorders in which TNF activity is detrimental.
A method of treating TNF disorder described, wherein the method comprises administering a lower dosage amount of a TNF inhibitor.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Ligand screening and discovery

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Dyax Corp. patent solves the following problem:

Artificial methods that allowed the discovery of artificial and natural protein wide applications in the development of therapeutics, diagnostic agents (for example, for imaging or binding assays), enzymes, and agents for affinity divorce. One such artificial means is the building of nucleic acid library that includes different content file. Library will screen Hybridization, genetic complementation, and polypeptide expression, among other activities. A challenge for the development of the artificial protein is rapidly identify functional proteins in the context of their last therapeutic or industrial use.

Our analysis of this patent is as follows:

Dyax Corp.’s patent US 8846579 B2 deals with Ligand screening and discovery.
Signifies is a strategy that includes: (i) providing a plurality of initial nucleic acid cassettes include: a) a first coding region encoding a first immunoglobulin variable domain , b) a second coding region encoding a second immunoglobulin variable domain, and c) a ribosomal price disposed between the first and second coding regions for the interpretation of the second polypeptide in a first expression system, where the first and second coding regions are in the same translation orientation; (Ii) modification of each nucleic acid cassette of the mass in a reaction mixture as it is used in a second expression system, wherein the first and second regions remained physically attached to describe; (Iii) identify each modified nucleic acid cassette to a mammal cell to produce a mixture of transfected cells; and (iv) expressing each modified nucleic acid cassette in transfected cells.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Identification of bacterial species and subspecies using lipids

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Colorado State University Research Foundation patent solves the following problem:

Bacteria often detected in the context of the diseases they cause, but some infectious diseases are specific enough that a doctor treating them directly. But, even for diseases proof required. The most common way to them directly by the culture of a specific pathogen, which was for many pathogens gold-standard in the detection and determination of infectious diseases. The second most used method for defining an infectious disease and the causative agent is the direct recognition by the antibody detection in all bacteria, crude extracts, fragments of the pathogen, or single molecule. Indirect methods to identify the disadvantage of recognition of other bacteria instead of the actual pathogen due to cross-reactivity with extracts, partial, or full of bacteria. Therefore, such tests only provide a first step towards recognition. Of particular interest are the trials that focus on single molecules like proteins. However, such trials have proved that species-, subspecies-, or species-specific, and thus, sharing the same disadvantages as that is for the whole extracts or fractions of whole bacteria (that is, the cross-reactivity, as an example).

Our analysis of this patent is as follows:

Colorado State University Research Foundation’s patent US 8846372 B2 deals with Identification of bacterial species and subspecies using lipids.
The use of free, extractable lipid found in bacteria to identify the bacterial species and varieties described. Bacteria found enough in their lipid composition to get effects on them using thin layer chromatographic techniques. Burkholderia pseudomallei, Burkholderia thailandensis, and Burkholderia mallei known in this way. Lipopeptides specific to Mycobacterium avium paratuberculosis, but not to be closely related to the bacteria Mycobacterium avium avium also used as a basis for the bacterial kind of recognition the use of mass spectrometry and seroreactivity. Mass spectrometric analysis of total bacterial lipid Burkholderia pseudomallei, Burkholderia thailandensis, and Burkholderia mallei, and mass spectrometric analysis of total bacterial lipid for Mycobacterium avium paratuberculosis and Mycobacterium avium avium, without additional lipid separation , showed that species, and the species of bacteria may be identified using such analysis.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.